#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Prof. Miloš Broďák: Introduction of new drugs has significantly improved results even in progressive and recurrent prostate cancers

The prognosis and treatment outcomes for patients with various stages of prostate cancer have significantly improved over the past two decades thanks to a number of new or improved modalities of diagnosis and therapy. We should soon benefit from newly introduced screening, or early detection programs, for these tumors. We briefly speak with Prof. MUDr. Miloš Broďák, Ph.D., head of the Urology Clinic of the Medical Faculty of Charles University and University Hospital Hradec Králové, about the latest advancements and challenges in this field, and comprehensively summarize the current options and procedures available today.
Source: Oncological Treatment 3. 4. 2024

News View on the Treatment of Rheumatoid Arthritis with Baricitinib Using the NNT Indicator

Clinical parameters assessed by patients themselves are an important tool in evaluating the effectiveness of new drugs and are particularly significant in the evaluation of treatments for chronic painful conditions, such as rheumatoid arthritis (RA). An analysis of clinical trial results presented at the European Rheumatology e-Congress in June 2020 focused on the effectiveness of the Janus kinase inhibitor baricitinib on parameters assessed directly by patients. Effectiveness was analyzed using the NNT indicator.
Source: Biological Treatment 30. 11. 2020

News How to Communicate and Receive an Oncological Diagnosis

Communicating the truth to a patient about their health condition does not have a very long tradition in the Czech Republic. The Czech healthcare system started emphasizing this aspect, i.e., honest and open communication between doctor and patient, several years after the Velvet Revolution.
Source: Ovarian and Breast Cancer 4. 6. 2020

News TTR amyloidosis – at the crossroads of cardiology and orthopedics

In wild-type transthyretin amyloid cardiomyopathy, extra-cardiac symptoms occur in addition to cardiac symptoms. Common and characteristic orthopedic manifestations include bilateral carpal tunnel syndrome, spinal canal stenosis in the lumbar region, or atraumatic rupture of the m. biceps brachii tendon. These extra-cardiac symptoms often precede the actual heart involvement. Recognizing them can thus increase diagnostic suspicion for cardiac amyloidosis and help in the timely establishment of the correct diagnosis and initiation of specific treatment. For example, even a rheumatologist or orthopedist can direct an elderly patient with an otherwise unexplained constellation of musculoskeletal symptoms to cardiology examination early, thereby significantly improving the patient's prognosis.
Source: Amyloidosis 14. 6. 2023

Journal articles Telemedicine and inflammatory bowel disease – results of the IBD Assistant pilot project

Author of the article: Malíčková K., Pešinová V., Bortlík M., Ďuricová D., Machková N., Hrubá V., Lukáš M. Jr., Mitrová K., Vašátko M., Kostrejová M., Kolář M., Lukáš M. Source: Gastroenterologie a hepatologie | 1/2020 25. 2. 2020

News Possibilities of Cannabis Use in Tourette Syndrome Therapy

A retrospective analysis and online survey conducted at a psychiatric clinic in Hanover, Germany, investigated the effectiveness and safety of using cannabis products in patients with Tourette syndrome in real-world practice.
Source: Medical Cannabis 20. 6. 2024

News Inhibitor of Activated Factor XII Garadacimab in Prophylaxis of HAE Attacks

Hereditary angioedema (HAE) is an autosomal dominant inherited disease characterized by a deficiency of C1 inhibitor. This condition leads to excessive production of bradykinin, which is responsible for the development of soft tissue edema. Garadacimab represents a human antibody, the first of its class, aimed at inhibiting activated factor XII, a key initiator of bradykinin formation. The phase II study presented below, whose results were recently published, evaluated the efficacy and safety of this innovative HAE therapy.
Source: Hereditary Angioedema 14. 11. 2022

News Longer survival without liver transplant in patients with PBC treated with OCA?

Obeticholic acid (OCA) is a second-line treatment for patients with primary biliary cholangitis (PBC) who have an inadequate response to ursodeoxycholic acid (UDCA) or intolerance to it. The study presented below, the results of which were recently published, examined the effectiveness of OCA in reducing cholestatic enzymes as well as the length of survival without liver transplant in patients with PBC.
Source: Primary Biliary Cholangitis 20. 3. 2023

News Albuminuria as a Risk Factor for Cardiovascular Events and Mortality in Patients with Type 2 Diabetes Without Apparent Cardiovascular Disease

Albuminuria in patients with type 2 diabetes is associated with a higher risk of cardiovascular (CV) events and higher mortality. However, this association has not been thoroughly investigated in diabetics without evident atherosclerotic disease. A study with a large cohort of Danish patients helped fill in the missing data.
Source: Diabetes 12. 4. 2022

News Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL

Polatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component of the B-lymphocyte receptor typically expressed by diffuse large B-cell lymphoma (DLBCL) cells. In combination with bendamustine and rituximab (pola-BR), this drug is administered in the 3rd and subsequent lines of treatment for relapsed or refractory (R/R) DLBCL. If allogeneic hematopoietic stem cell transplantation (HSCT) is not feasible, patients with R/R DLBCL generally have a very poor prognosis, with limited further treatment options. However, at the 61st American Society of Hematology (ASH) congress held in December 2019 in Orlando, promising results were presented from extended follow-up of patients treated in clinical studies with the pola-BR combination.
Source: Non-Hodgkin Lymphomas and CLL 3. 2. 2020

News INFOGRAPHIC: Eye Drops for Dry and Irritated Eyes – Mechanism of Action and Benefits

Source: Ophthalmologic Diseases 2. 5. 2023

News Targeted Treatment of HER2-Positive Breast Tumors – Updates from ESMO 2020 Congress

The recent European Society for Medical Oncology (ESMO) Congress took place virtually. We bring you a brief summary of the presentations related to the treatment of HER2-positive breast tumors.
Source: Breast Carcinoma 11. 1. 2021

News Impact of Lifestyle on the Benefit of Pharmacotherapy for Hypertension and Dyslipidemia

Antihypertensive and hypolipidemic therapy reduces the risk of cardiovascular (CV) diseases. Observational studies have shown that factors of a healthy lifestyle also have this influence. But is the benefit of pharmacotherapy for hypertension and dyslipidemia influenced by adherence to a healthy lifestyle? This question was attempted to be answered by an analysis of data from the clinical study HOPE-3.
Source: Sartans in the Treatment of Hypertension 18. 4. 2020

News Educational Quiz (For Downtime)

The following quiz has been prepared for you as an activity for relaxation and unwinding from today's hectic days. In an easy manner, it will refresh your knowledge about immune cells and may even offer some education or entertainment.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 20. 4. 2020

News Picking from the Red Book of the CHS: What's New in This Year's Recommendations for Diagnosis and Treatment of AML?

In recent years, there have been significant advances in the diagnosis and therapy of acute myeloid leukemia (AML). High-quality laboratory diagnostics (molecular genetics, cytogenetics, and flow cytometry) are absolutely essential, and monitoring measurable residual disease is becoming increasingly important. The range of treatment options is also beginning to expand. The content of the latest 'Recommendations for the Diagnosis and Treatment of Acute Myeloid Leukemia (AML),' which are part of this year's updated 'Red Book' of the Czech Hematology Society ČLS JEP (CHS), is primarily based on the 2022 European Leukemia Network (ELN) guidelines and offers, among other things, an updated disease classification and risk stratification, as well as an overview of current treatment options for both intensive and non-intensive regimens.
Source: Acute Myeloid Leukemia 29. 11. 2023

News Efficacy of Hyaluronic Acid Eye Drops in the Treatment of Dry Eye Syndrome – Results of a Meta-Analysis

Dry eye syndrome affects 5–30% of individuals over the age of 50. The beneficial effect of hyaluronic acid on the symptoms of this condition has been well described in both preclinical and clinical studies, and it has been shown that its topical application increases the secretion of water and mucin on the surface of the eye. The meta-analysis presented below focused on the efficacy of eye drops containing hyaluronic acid in the treatment of dry eye syndrome.
Source: Ophthalmologic Diseases 13. 3. 2023

News Rapid Diagnosis of Depression in Primary Care Settings

Depression is one of the most commonly occurring psychiatric disorders encountered in general practitioners' offices. The general public also very often uses the term “depression” to mean “bad mood.” Thus, a rapid diagnostic tool to identify “real depression” certainly deserves our attention.
Source: Depression and Anxiety 17. 3. 2020

News Expanded Hemodialysis and Its Impact on Reducing Hospitalization Rates and Medication Usage

The number of patients with end-stage kidney disease is increasing. New approaches and technological advancements in recent decades have contributed to improving hemodialysis treatment. Does the use of so-called expanded hemodialysis lead to better outcomes?
Source: Chronic Kidney Disease 30. 11. 2021

News Trifluridine/tipiracil in Real Clinical Practice – Current Data from Spain

Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal cancer (mCRC), where clinical studies have shown it extends overall survival (OS) and progression-free survival (PFS). At this year's virtual World Congress on Gastrointestinal Cancer of the European Society for Clinical Oncology (ESMO), held from June 30, a Spanish study on the efficacy of trifluridine/tipiracil in real-world clinical practice was presented.
Source: Treatment of Gastrointestinal Carcinomas 9. 9. 2021

News Bimekizumab in the Treatment of Psoriatic Arthritis

Arthritis can appear in up to a third of patients with psoriasis, mostly after the onset of skin symptoms. Early recognition of this transition by dermatologists and general practitioners is crucial, as early intervention can prevent irreversible joint damage. In the context of effective biological therapy, there is even talk of the potential prevention of arthritis development in individuals with psoriasis.
Source: Rheumatic Diseases 20. 6. 2024

News Doc. Petr Dulíček: Physical activity in hemophiliacs? Today it is a reality - just don't be afraid!

Thanks to modern treatment, the lives of hemophiliacs are becoming more active. Patients today can engage in most sports activities. On the contrary, avoiding physical activity carries the risk of developing other diseases. A doctor should support their patients so they are not afraid of physical activities and highlight their benefits, says the head of the Center for Hemostasis Disorders at the IV. Internal Hematology Clinic of LF UK and FN Hradec Králové, Doc. MUDr. Petr Dulíček, Ph.D., in an interview on hemophilia and sports.
Source: Hemophilia with Movement 30. 5. 2022

News Induction vs. Escalation Treatment: Which Strategy to Choose in the Therapy of Multiple Sclerosis?

Opinions on the optimal therapy for multiple sclerosis (MS) are constantly evolving, and experts are debating the most appropriate first-line treatment strategy. A British cohort study focused on the long-term outcomes of induction and escalation therapies, two key approaches in the treatment of MS.
Source: Multiple Sclerosis 25. 6. 2020

News Nearly 20 Years with Bevacizumab Has Brought Hope for Patients and Deeper Understanding of Solid Tumors

Bevacizumab is among the first targeted therapies used in oncology. For many indications where chemotherapy options had been exhausted and few other treatment modalities were available, it changed the treatment approach and brought patients prolonged progression-free survival or even overall survival. It has become a standard of care for many advanced cancers. What do we know today about this monoclonal antibody, first introduced in routine practice in 2005?
Source: Oncological Treatment 19. 8. 2022

News Spiolto Respimat System – Innovation for Easier Inhalation

Inhalation delivery is the most preferred method of drug administration in chronic obstructive pulmonary disease and bronchial asthma. The effectiveness of therapy is also conditioned by the correct inhalation technique. The aim of the following article is a brief comparison of inhalation systems, focusing on a new addition to the group of aerosol inhalers.
Source: COPD 16. 3. 2020

News Measurement of Serum Trough Levels of IgG as an Adequate and Beneficial Indicator for Assessing the Pharmacokinetics of Subcutaneously Administered Products

For many patients with primary immunodeficiency, lifelong immunoglobulin substitution is essential to reduce the frequency of severe infections. Subcutaneous home administration is better accepted by patients. However, dosing needs to be customized to the patient. The study presented below may help make therapy individualization easier for doctors and more tolerable for patients.
Source: Primary and Secondary Immunodeficiencies 11. 4. 2023

1 34 35 36 37 38 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#